SC
HZNP

Sagefield Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Sagefield Capital’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,200
Closed -$1.53M – 122
2023
Q3 		$1.53M Buy
13,200
+9,300
+238% +$999K 0.21% 68
2023
Q2 		$401K Sell
3,900
-3,700
-49% -$390K 0.09% 83
2023
Q1 		$829K Sell
7,600
-8,800
-54% -$973K 0.19% 73
2022
Q4 		$1.87M Buy
+16,400
New +$1.36M 0.47% 45

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Sagefield Capital's HZNP Position: Q4 2023 in Review

Sagefield Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 13,200 shares — an estimated $1.53M sold.

Sagefield Capital first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $1.87M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Sagefield Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Sagefield Capital sold 13,200 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1.53M.
  • Sagefield Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • Sagefield Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.87M in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Sagefield Capital's 13F filing for Q4 2023, filed 14 Feb 2024.